Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products… Read more
Jiangsu Aidea Pharmaceutical Co Ltd - Asset Resilience Ratio
Jiangsu Aidea Pharmaceutical Co Ltd (688488) has an Asset Resilience Ratio of 4.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Aidea Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.18 Million | 4.35% |
| Total Liquid Assets | CN¥80.18 Million | 4.35% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Aidea Pharmaceutical Co Ltd maintains only 4.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Aidea Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Aidea Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Jiangsu Aidea Pharmaceutical Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Aidea Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.68% | CN¥106.18 Million | CN¥1.87 Billion | -6.67pp |
| 2023-12-31 | 12.35% | CN¥215.75 Million | CN¥1.75 Billion | -8.89pp |
| 2022-12-31 | 21.24% | CN¥351.64 Million | CN¥1.66 Billion | +9.86pp |
| 2021-12-31 | 11.38% | CN¥163.31 Million | CN¥1.43 Billion | -25.68pp |
| 2020-12-31 | 37.07% | CN¥536.31 Million | CN¥1.45 Billion | -- |